Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calcium release in a dosage dependent manner

Biochemical and Biophysical Research Communications

Volumn 432, Issue 3, 2013, Pages 431-437

  Pan, Zhi ^a,b   Gollahon, Lauren ^a  

^a TEXAS TECH UNIVERSITY   (United States)

^b Division of Public Health ^*  (United States)

Author keywords

Apoptosis; Bcl 2; Breast cancer; Calcium; Endoplasmic reticulum; Paclitaxel

Indexed keywords

PACLITAXEL; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CALCIUM TRANSPORT; CONTROLLED STUDY; CYTOSOL; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CALCIUM; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; FEMALE; HUMANS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84875001806     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.130     Document Type: Article

References (40)

1. Igney F.H., Krammer P.H. Death and anti-death: tumor resistance to apoptosis. Nat. Rev. Cancer 2002, 2:277-288.
2. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
3. Brown J.M., Wouters B.G. Apoptosis: mediator or mode of cell killing by anticancer agents?. Drug Resist. Updat. 2001, 4:135-136.
4. Brown M., Wilson G. Apoptosis genes and resistance to cancer therapy. Cancer Biol. Ther. 2003, 2(5):477-490.
5. Cory S., Adams J.M. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2:647-656.
6. Murray S., Briasoulis E., Linardou H., et al. Taxane resistance in breast cancer Mechanisms predictive biomarkers and circumvention strategies. Cancer Treat. Rev. 2012, 890-903.
7. Sekine I., Shimizu C., Nishio K., et al. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int. J. Clin. Oncol. 2009, 14(2):112-119.
8. Nuydens R., Dispersyn G., Van Den Kieboom G., et al. Bcl-2 protects neuronal cells against taxol-induced apoptosis by inducing multi-nucleation. Apoptosis 2000, 5:335-343.
9. Yang Q., Sakurai T. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol. Rep. 2003, 10:121-125.
10. Ferlini C., Raspaglio G. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol. Pharmacol. 2003, 64:51-58.
11. Yoshino T., Shiina H., Urakami S., et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin. Cancer Res. 2006, 12:6116-6124.
12. Poelman S.M., Adeyanju M.O. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin. Cancer Res. 2000, 6:4043-4048.
13. Tabuchi Y., Matsuoka J., Gunduz M., et al. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int. J. Oncol. 2009, 34(2):313-319.
14. Maráz A., Furák J., Pálföldi R. Roles of Bcl-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Anticancer Res. 2011, 31(4):1431-1436.
15. Demaurex N., Distelhorst C. Apoptosis-the calcium connection. Science 2003, 300:65-67.
16. Breckenridge D.G., Germain M., Mathai J.P., et al. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 2003, 22:8608-8618.
17. Rao R.V., Ellerby H.M., Bredesen D.E. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ. 2004, 11:372-380.
18. 2+ transport. Nat. Rev. Cancer 2007, 7:519-530.
19. Berridge M.J. The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium 2002, 32:235-249.
20. Szabadkai G., Rizzuto R. Participation of endoplasmic reticulum and mitochondrial calcium handling in apoptosis: more than just neighborhood?. FEBS Lett. 2004, 567:111-115.
21. Hitomi J., Katayama T., Taniguchi M., et al. Apoptosis induced by endoplasmic reticulum stress depends on activation of caspase-3 via caspase-12. Neurosci. Lett. 2004, 357:127-130.
22. Lamkanfi M., Kalai M., Vandenabeele P. Caspase-12: an overview. Cell Death Differ. 2004, 11:365-368.
23. 2+ mobilization. Am. J. Physiol. 1998, 275:C832-C839.
24. Distelhorst C.W., Shore G.C. Bcl-2 and calcium: controversy beneath the surface. Oncogene 2004, 23:2875-2880.
25. 2+ concentrations determine the extent and the morphological type of apoptosis, respectively. Ann. N.Y. Acad. Sci. 2003, 1010:74-77.
26. 2+ homeostasis and apoptosis. EMBO J. 2004, 23:1207-1216.
27. 2+-ATPase (SERCA). Biochem. J. 2004, 383:361-370.
28. 2+ homeostasis and store-operated channels in prostate cancer cells. Cancer Cell 2002, 1:169-179.
29. Rong Y.P., Distelhorst C.W., et al. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc. Natl. Acad. Sci. USA 2009, 106(34):14397-14402.
30. Pan Z., Gollahon L. Taxol directly induces endoplasmic reticulum-associated calcium changes that promote apoptosis in breast cancer cells. Breast J. 2011, 17(1):56-70.
31. Liao P.C., Tan S.K., Lieu C.H., et al. Involvement of endoplasmic reticulum in paclitaxel-induced apoptosis. J. Cell. Biochem. 2008, 104(4):1509-1523.
32. Taxol (Paclitaxel) injection product information. Princeton, NJ: Bristol-Myers Squibb Company (2007). http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=27377.
33. MDA-MB-468 breast carcinoma cell line product description. Manassas, VA: American Tissue Culture Center, (2008). http://www.atcc.org/Products/All/HTB-132.aspx#357C3571006A4259B64650D34DF19048.
34. Wang N.S., Unkila M.T., Reineks E.Z., et al. Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death. J. Biol. Chem. 2001, 276:44117-44128.
35. 2+ indicators based on computationally redesigned calmodulin-peptide pairs. Chem. Biol. 2006, 13:521-530.
36. Palmer A.E., Tsien R.Y. Measuring calcium signaling using genetically targetable fluorescent indicators. Nat. Protoc. 2006, 1:1057-1065.
37. Rodi D.J., Janes R.W., Sanganee H.J., et al. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J. Mol. Biol. 1999, 285:197-203.
38. Ferlini C., Cicchillitti L., Raspaglio G., et al. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009, 69(17):6906-6914.
39. Brichese L., Barboule N., Heliez C., et al. Bcl-2 phosphorylation and proteasome-dependent degradation induced by paclitaxel treatment: consequences on sensitivity of isolated mitochondria to bid. Exp. Cell Res. 2002, 278:101-111.
40. Asnaghi L., Calastretti A., Bevilacqua A., et al. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004, 23:5781-5791.